Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to Strong Sell at Wall Street Zen

Enanta Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Enanta Pharmaceuticals from “sell” to “strong sell.” Other analyst views remain mixed: the consensus rating is “Moderate Buy,” with an average price target of $19.
  • Enanta’s latest quarter fell short of expectations, reporting a loss of $0.81 per share versus an expected $0.72 loss and revenue of $12.87 million versus a $14.62 million consensus.
  • Shares opened at $7.62, near the stock’s 12-month low of $7.56; the 12-month high is $17.15.
  • MarketBeat previews the top five stocks to own by December 1st.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Saturday, Wall Street Zen reports.

ENTA has been the topic of a number of other reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Thursday, October 15th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Finally, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $19.00 to $17.00 and set an "overweight" rating for the company in a report on Friday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $19.00.

Check Out Our Latest Research Report on ENTA

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $7.62 on Friday. Enanta Pharmaceuticals has a 12 month low of $7.56 and a 12 month high of $17.15. The company's 50-day moving average price is $11.48 and its 200-day moving average price is $12.97.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.09). The company had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.62 million. Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 59.48%. As a group, equities research analysts expect that Enanta Pharmaceuticals will post -2.24 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company's stock worth $47,717,000 after buying an additional 54,396 shares in the last quarter. Jupiter Topco LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter worth $53,252,000. BlackRock Inc. purchased a new stake in Enanta Pharmaceuticals during the second quarter worth $47,304,000. ADAR1 Capital Management LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter worth $19,603,000. Finally, Spruce Street Capital LP bought a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at $15,873,698. 94.99% of the stock is currently owned by institutional investors.

Latest Enanta Pharmaceuticals News

Here's some of the latest news about ENTA:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, while raising its FY2027–FY2030 earnings estimates to reflect smaller projected losses. This signals improved longer-term expectations, though the forecasts still show losses. MarketBeat report
  • Neutral Sentiment: JPMorgan cut its price target to $17 from $19 but kept an Overweight rating. The lower target is a negative revision, while the rating and implied upside from the cited $7.62 share price remain supportive.
  • Negative Sentiment: Enanta’s latest reported quarter missed expectations: its loss per share was wider than analysts forecast, and revenue came in below estimates. The results may weigh on sentiment amid the analyst updates. MarketBeat earnings information

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta's work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company's history of applying its drug-discovery expertise to antiviral therapies.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?

Before you consider Enanta Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.

While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines